The French drug safety agency on Wednesday announced it was stepping up monitoring of Ozempic, a diabetes drug promoted by influencers on social networks who flaunt its weight-loss properties. As well as health concerns, the authorities say the increased demand could jeopardise access for legitimate diabetic patients.
In a joint press release with the national health insurance agency, the ANSM said "reports from the field show misuse in non-diabetic people with the aim of weight loss".
